Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is expressed on the surface of some tumor epithelial cells and is a potential therapeutic target for antibody-drug conjugates, such as tusamitamab ravtansine, in development.
An immunohistochemistry (IHC) assay has been validated in multiple cancer indications, including non-small cell lung cancer (NSCLC), for evaluation of clinical samples using a proprietary CEACAM5-specific murine antibody (Sanofi CEACAM5 IHC monoclonal antibody clone 769 [Sanofi clone 769]) and the Dako/Agilent Autostainer Link 48 platform4.
In this poster, the authors compare 5 commercially available monoclonal antibody (mAb) clones targeted to CEACAM5 with the validated CEACAM5 antibody Sanofi clone 769.
